Payment overview · 2025
General Payments
$1,271.20
48 reported records · 11 companies
Healthcare provider profile · identity verified
Jason Ceavers, MD
Allopathic & Osteopathic Physicians|General Practice · WILTON MANORS, FL · NPI 1205497005
Verified facts
What the public records show
CMS Open Payments records show Jason Ceavers, MD received $1,271.20 in general payments during 2025 across 48 reported records.
ViiV Healthcare Company accounted for 42.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Dovato, Ozempic.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Serostim as an associated drug or biological on 153 records involving 74 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Serostim by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Descovy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Wegovy by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $541.86 | 42.6% | 20 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $267.37 | 21.0% | 16 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $147.16 | 11.6% | 1 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $90.91 | 7.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.60 | 3.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.29 | 2.9% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $35.31 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.63 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.91 | 2.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.73 | 2.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.43 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,271.20 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $500.73 | 17 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $147.16 | 1 | 2025 |
Source payment records
|
|||||
| Phasix Mesh Normalized: phasix mesh |
Device | Davol Inc. | $90.91 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $41.13 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.29 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $32.63 | 1 | 2025 |
Source payment records
|
|||||
| DELSTRIGO Normalized: delstrigo |
Drug | Merck Sharp & Dohme LLC | $32.63 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $32.63 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.91 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.91 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.73 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $18.84 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 148 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Serostim open payments reported associated product |
CMS Open Payments — General Payments 153 supporting records · 74 recipient NPIs · example record 1236871463 |
Serostim · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
148 | 22 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 588 | 219 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 479 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 104 |
| Losartan Potassium | Losartan Potassium | 227 | 82 |
| Alprazolam | Alprazolam | 205 | 60 |
| Metformin Hcl | Metformin Hcl | 194 | 71 |
| Mounjaro | Tirzepatide | 182 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 168 | 62 |
| Omeprazole | Omeprazole | 167 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 59 |
| Lisinopril | Lisinopril | 155 | 62 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 148 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 48 |
| Gabapentin | Gabapentin | 136 | 53 |
| Bupropion Xl | Bupropion Hcl | 129 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 53 |
| Testosterone Cypionate | Testosterone Cypionate | 114 | 37 |
| Montelukast Sodium | Montelukast Sodium | 110 | 53 |
| Descovy | Emtricitabine/Tenofov Alafenam | 108 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 38 |
| Clonazepam | Clonazepam | 101 | 23 |
| Ezetimibe | Ezetimibe | 93 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 36 |
| Ozempic | Semaglutide | 90 | 24 |
| Trazodone Hcl | Trazodone Hcl | 90 | 37 |
| Telmisartan | Telmisartan | 84 | 24 |
| Irbesartan | Irbesartan | 83 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 28 |
| Famotidine | Famotidine | 74 | 26 |
| Allopurinol | Allopurinol | 73 | 25 |
| Azithromycin | Azithromycin | 72 | 60 |
| Finasteride | Finasteride | 69 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 24 |
| Carvedilol | Carvedilol | 66 | 23 |
| Eliquis | Apixaban | 66 | 23 |
| Anastrozole | Anastrozole | 65 | 26 |
| Temazepam | Temazepam | 59 | suppressed |
| Lorazepam | Lorazepam | 58 | 19 |
| Testosterone | Testosterone | 56 | 19 |
| Furosemide | Furosemide | 52 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 16 |
| Valacyclovir | Valacyclovir Hcl | 50 | 23 |
| Metformin Hcl Er | Metformin Hcl | 48 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 11 |
| Sertraline Hcl | Sertraline Hcl | 47 | 15 |
| Tramadol Hcl | Tramadol Hcl | 47 | 12 |
| Tivicay | Dolutegravir Sodium | 46 | suppressed |
| Chlorthalidone | Chlorthalidone | 44 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 17 |
| Diazepam | Diazepam | 40 | 11 |
| Meloxicam | Meloxicam | 39 | 17 |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 38 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 23 |
| Wegovy | Semaglutide | 36 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 11 |
| Pregabalin | Pregabalin | 31 | 13 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 27 |
| Simvastatin | Simvastatin | 28 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Valsartan | Valsartan | 27 | 11 |
| Acyclovir | Acyclovir | 26 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Prednisone | Prednisone | 23 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 21 |
| Prezcobix | Darunavir/Cobicistat | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Atenolol | Atenolol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 12 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 13 |
| Oxycontin | Oxycodone Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Serostim | Somatropin | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,271.20 · 48 records | ViiV Healthcare Company | APRETUDE, Biktarvy, CAPVAXIVE, CLOT MANAGEMENT, Cologuard Collection Kit, DELSTRIGO, DOVATO, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, OTEZLA, Ozempic, PIFELTRO, Phasix Mesh, REPATHA, Rybelsus | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with EMD Serono, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error